Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPEL: PTG-100 in Ulcerative Colitis
NCT02895100Phase 2Terminated
- Sponsor
- Protagonist Therapeutics, Inc.
- Start
- Dec 2016
- Primary completion
- Mar 2018
- Modality
- Peptides, Small Molecules
- Countries
- 17
01
Overview
A Phase 2 trial of PTG-100 in ulcerative colitis (UC), sponsored by Protagonist Therapeutics, Inc.. Started Dec 2016; status: terminated.
02
Drugs
PTG-100
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02895100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02895100.